March 24, 2026
The global stem cells market was valued at approximately $15.10 billion in 2024 and is projected to reach $28.89 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.41%, according to Grand View Research. The United States stem cell therapy market was valued at $5.99 billion in 2024 and is projected to reach $19.54 billion by 2034 at a CAGR of 12.55%, according to Precedence Research (2025). Stem cell therapy providers operating in Tennessee must register with the Tennessee Secretary of State and comply with local business tax requirements through the Tennessee Taxpayer Access Point (TNTAP) at tntap.tn.gov, where a $15 business license registration fee is payable to the applicable county or city clerk. Medical practitioners offering stem cell procedures in Tennessee must hold an active license issued by the Tennessee Board of Medical Examiners under the Tennessee Medical Practice Act (TCA § 63-6-101 et seq.).
Nashville’s concentration of healthcare systems, academic medical research institutions, and a growing regenerative medicine sector sustains demand for stem cell services that extends beyond what a metropolitan area of its size would ordinarily generate. The Nashville metropolitan statistical area, anchored by Davidson County and extending into Williamson, Rutherford, and Sumner counties, hosts one of the largest healthcare industry corridors in the United States, with major systems including Vanderbilt University Medical Center and HCA Healthcare headquartered in the region. North America accounted for the largest share of the global stem cells market in 2024, with approximately 43.89% of revenue, according to Grand View Research, driven by extensive research and development activity, favorable regulatory frameworks, and high adoption of stem cell-based therapies. Adult stem cells (ASCs) represented approximately 70.76% of the global stem cells market by product in 2024, according to Grand View Research, reflecting their established safety profile, ethical acceptability, and clinical track record in treating orthopedic injuries, blood disorders, and autoimmune conditions.
Nashville’s regenerative medicine landscape reflects a range of provider models offering different cell sourcing approaches, treatment protocols, and regulatory postures. The distinction between autologous therapies, which use cells harvested from the patient’s own body (typically bone marrow or adipose tissue), and allogeneic therapies, which use donor-derived cells (such as umbilical cord tissue), represents a foundational difference in how Nashville-area clinics structure their services. Providers using autologous cells processed on-site during the same surgical procedure may operate under the same surgical procedure exception outlined in 21 CFR 1271.15(b), while providers using allogeneic products or more-than-minimally-manipulated cells are subject to additional FDA oversight under 21 CFR Part 1271.
The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. An HCT/P is regulated solely under Section 361 of the Public Health Service Act — and exempt from premarket FDA approval as a drug or biologic — only if it meets all four criteria in 21 CFR 1271.10(a): the product is minimally manipulated, intended for homologous use only, its manufacture does not involve combination with another article (with limited exceptions), and it either has no systemic effect or is for autologous use. Products that do not meet all four criteria are regulated as drugs, devices, or biological products and are subject to FDA premarket review requirements. As of 2024, the only stem cell products with full FDA approval for use in the United States consist of hematopoietic progenitor cells derived from umbilical cord blood, approved for patients with disorders affecting blood production. Tennessee consumers considering stem cell therapy are protected under the Tennessee Consumer Protection Act of 1977 (TCA § 47-18-104), which prohibits unfair or deceptive acts affecting trade or commerce and allows injured consumers to seek actual and treble damages. Verifying that advertised treatment claims, outcome representations, and cell sourcing descriptions are accurate and substantiated with specific supporting information serves as a check on provider credibility. For consumer complaints or rights inquiries, the Tennessee Division of Consumer Affairs is accessible at tn.gov/consumer.
Top Stem Cell Therapy Providers in Nashville
Vita Nova Stem Cell Professionals
Address: 4601 Carothers Parkway, Suite 325, Franklin, TN 37067 Phone: (615) 801-8005 Website: vitanovatn.com
Description: Vita Nova Stem Cell Professionals is a regenerative medicine practice located in Franklin, Tennessee, serving patients throughout the greater Nashville area and Middle Tennessee. The practice was founded by a board-certified physician specializing in regenerative therapies, with a focus on using patients’ own cells (autologous approach) rather than donor-derived materials. Vita Nova maintains an in-house laboratory where autologous cells harvested from the patient’s own body are processed on-site under direct physician supervision, rather than being shipped to an external facility, allowing the entire process from cell harvesting to treatment to occur in a single location during a single visit. The practice provides documented cell counts and viability reports showing the composition of what is delivered during each procedure. Vita Nova’s treatment areas include orthopedic conditions, neurological conditions, systemic and organ-related concerns, and wellness applications. The practice also offers platelet-rich plasma (PRP) injections, Alpha-2-Macroglobulin (A2M) therapy for cartilage protection and joint inflammation, and IV nutrient infusion therapy. Vita Nova structures each patient’s care around an individualized plan developed after consultation, with treatment protocols tailored to the patient’s specific condition, goals, and medical history.
Stem Cell Therapy Center of Nashville
Address: 1909 Mallory Lane, Suite 302D, Franklin, TN 37067 Phone: (615) 905-4994 Website: stemcelltherapycenternashville.com
Description: The Stem Cell Therapy Center of Nashville is a regenerative medicine clinic located in Franklin, Tennessee. The clinic offers stem cell therapy, exosome therapy, and platelet-rich plasma (PRP) injections. Treatment areas listed by the provider include orthopedic injuries, neurological disorders, cardiac conditions, autoimmune conditions, and cosmetic applications including hair loss treatment. The clinic also provides exosome-based anti-aging therapy. The Stem Cell Therapy Center of Nashville reports that patients may begin seeing signs of improvement within 30 days, though individual outcomes vary by condition and patient profile.
R3 Stem Cell — Nashville / Brentwood
Address: 5020 Thoroughbred Lane, Brentwood, TN 37027 Phone: (844) 438-7836 Website: r3stemcell.com
Description: R3 Stem Cell operates a Nashville-area location in Brentwood, Tennessee, within the Merchant’s Walk Shopping Center, as part of a national network with over 45 centers across seven countries. The Brentwood clinic offers stem cell therapy using umbilical cord allograft tissue (allogeneic approach), exosome therapy, and PRP treatments. R3 Stem Cell reports having performed over 21,000 procedures across its network. The practice provides free initial consultations by phone or in person. Treatment areas listed by the provider include joint pain, neuropathy, autoimmune conditions, COPD, and sexual health concerns including erectile dysfunction and vaginal rejuvenation. R3 also offers hormone replacement therapy including bioidentical hormones.
Frequently Asked Questions
What federal regulations govern stem cell therapy in Tennessee?
The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. An HCT/P is exempt from premarket FDA approval only if it meets all four criteria in 21 CFR 1271.10(a): minimal manipulation, homologous use, no combination with another article (with limited exceptions), and either no systemic effect or autologous use. Products that do not meet all four criteria are regulated as drugs, devices, or biological products requiring premarket review. The FDA’s framework for regenerative medicine products is available at fda.gov.
Are stem cell therapies FDA-approved?
As of 2024, the only stem cell products with full FDA approval for use in the United States consist of hematopoietic progenitor cells derived from umbilical cord blood, approved for patients with disorders affecting the hematopoietic (blood-producing) system. Many regenerative medicine treatments offered at private clinics, including therapies using adipose-derived cells, expanded stem cells, or donor tissues for conditions such as joint pain, are not FDA-approved for those specific uses. The FDA maintains a consumer information page on regenerative medicine therapies at fda.gov.
What is the difference between autologous and allogeneic stem cell therapy?
Autologous stem cell therapy uses cells harvested from the patient’s own body, typically from bone marrow or adipose (fat) tissue, and reintroduced during the same procedure. Allogeneic stem cell therapy uses donor-derived cells, such as umbilical cord tissue or placental tissue. The regulatory pathway, risk profile, and clinical considerations differ between the two approaches. Autologous procedures performed within the same surgical procedure exception under 21 CFR 1271.15(b) may be subject to different regulatory requirements than allogeneic products or more-than-minimally-manipulated cells.
What licensing is required to offer stem cell therapy in Tennessee?
Physicians offering stem cell procedures in Tennessee must hold an active medical license issued by the Tennessee Board of Medical Examiners under the Tennessee Medical Practice Act (TCA § 63-6-101 et seq.). The practice location must comply with local business tax requirements, and businesses with gross receipts exceeding $3,000 must obtain at least a minimal activity license from the applicable county or city clerk. Establishments involved in the recovery, processing, storage, or distribution of HCT/Ps must register with the FDA under 21 CFR Part 1271, Subpart B.
How is the stem cell therapy market expected to grow?
The global stem cells market was valued at approximately $15.10 billion in 2024 and is projected to reach $28.89 billion by 2030 at a CAGR of 11.41%, according to Grand View Research. The United States stem cell therapy market was valued at $5.99 billion in 2024 and is projected to reach $19.54 billion by 2034 at a CAGR of 12.55%, according to Precedence Research (2025). North America accounted for approximately 43.89% of global stem cells market revenue in 2024. The regenerative medicine application segment represented the largest share of the market, reflecting growing clinical adoption of stem cell-based therapies for chronic and degenerative conditions.
How can Tennessee consumers evaluate a stem cell therapy provider’s claims?
Confirming whether a provider’s advertised treatment claims identify the specific cell source (autologous vs. allogeneic), processing method, and regulatory status of the products used provides a basis for evaluating the practice’s transparency. Verifying that the treating physician holds an active Tennessee medical license through the Tennessee Board of Medical Examiners, that the establishment is registered with the FDA if required under 21 CFR Part 1271, and that outcome claims are supported by published clinical evidence or clearly identified as individual patient experiences serves as a practical assessment framework. The Tennessee Division of Consumer Affairs at tn.gov/consumer is available for complaints related to deceptive business practices, and the FDA maintains a public query tool for verifying HCT/P establishment registration.